Market: NASD |
Currency: USD
Address: Tuborg Boulevard 12
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
📈 Ascendis Pharma A/S Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$248.89
-
Upside/Downside from Analyst Target:
29.09%
-
Broker Call:
34
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
50-100%
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-0.27
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Ascendis Pharma A/S
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-07 | -0.64 |
| 2025-05-01 | -1.58 |
| 2025-02-12 | -0.64 |
| 2024-11-14 | -1.72 |
| 2024-09-03 | -1.91 |
| 2024-05-02 | -2.3 |
| 2024-02-07 | -1.54 |
| 2023-11-07 | -2.88 |
| 2023-09-05 | -2.16 |
| 2023-04-27 | -1.98 |
| 2023-02-16 | -3.7 |
| 2022-11-02 | -3.03 |
| 2022-08-10 | -1.46 |
| 2022-05-11 | -2.21 |
| 2022-03-02 | -1.87 |
| 2021-11-10 | -1.47 |
| 2021-08-25 | -2.5 |
| 2021-05-27 | -1.17 |
| 2021-03-10 | -2.64 |
| 2020-11-11 | -2.31 |
| 2020-08-27 | -1.97 |
| 2020-05-19 | -1.32 |
| 2020-04-01 | -1.67 |
| 2019-11-18 | -0.53 |
📰 Related News & Research
No related articles found for "ascendis pharma".
